Uniphar Stock

Uniphar Financial Leverage

The Financial Leverage (Equity Multiplier) of Uniphar (UPR.IR) as of Aug 13, 2026 is 4.28. In the previous year, Financial Leverage (Equity Multiplier) was 3.52 — a change of 21.37% (higher).

Financial Leverage

4.28

YoY

21.37%

Last updated:

Financial Leverage (Equity Multiplier) of Uniphar is 2026 4.28 . Financial Leverage (Equity Multiplier) of Uniphar was 2025 3.52 . It decreases by 21.37% higher compared to the previous year.
Access this data via the Eulerpool API

Uniphar Stock analysis

What does Uniphar do? Uniphar PLC is an Irish company that was founded in 1994 and operates in the healthcare industry. The company is headquartered in Dublin and employs over 2,500 people worldwide. The history of Uniphar began as a pharmacy distribution company that supplied medications to retailers and healthcare facilities. Over the years, however, the company has expanded its business model and now offers a wide range of healthcare products and services. Uniphar's business model encompasses three main areas: Healthcare Services, Commercial & Clinical Supply Chain, and Product Access & Specialty Medicines. In the Healthcare Services area, Uniphar provides consulting services, training, and leadership coaching for healthcare facilities. The Commercial & Clinical Supply Chain division includes the storage, logistics, and distribution of medications, as well as the clinical care of patients. The Product Access & Specialty Medicines division focuses on access to medications with high medical demand and rare diseases. Uniphar also offers a wide range of healthcare products, including generics, branded medications, and medical devices. The company has partnerships with leading pharmaceutical companies such as Pfizer, Eli Lilly, and Merck. In recent years, Uniphar has also made several significant acquisitions to expand and diversify its business. In 2018, the company acquired UK-based pharmaceutical distributor Cahill May Roberts, and in 2019, the acquisition of Durbin, an international supplier of clinical supply products, was completed. Uniphar is committed to improving healthcare in Ireland and worldwide and offers a wide range of products and services to achieve this goal. The company has earned a reputation as a reliable partner for healthcare facilities and pharmaceutical companies and is on a steady growth trajectory. Uniphar is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uniphar stock

Financial Leverage (Equity Multiplier) of Uniphar is 4.28 in 2026.

Financial Leverage (Equity Multiplier) of Uniphar changed from 3.52 to 4.28, representing a 21.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Uniphar since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Uniphar with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Uniphar

All Key Metrics — Uniphar